Skip to search formSkip to main contentSkip to account menu

PF 3512676

Known as: PF-3512676, PF3512676 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Agatolimod SodiumProMune
CpG 7909

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Toll-like receptor agonists: a patent review (2011 – 2013)
Introduction: Toll-like receptors (TLRs) are a crucial part of the innate immunity and present the first line of defense against… 
Highly Cited
2013
Highly Cited
2013
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
Background:Tremelimumab, a fully human cytotoxic T-lymphocyte antigen 4 monoclonal antibody, and PF-3512676, a Toll-like receptor… 
Highly Cited
2012
Highly Cited
2012
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
BACKGROUND This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF… 
Highly Cited
2009
Highly Cited
2009
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse
The anti-tumor properties of Toll-like receptor (TLR) 9 agonist CpG oligodeoxynucleotides (ODN) are enhanced by combinations with… 
2009
2009
Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study.
PURPOSE Single-agent PF-3512676 (agatolimod), a Toll-like receptor 9 agonist, was examined in an open-label, single-arm… 
Highly Cited
2008
Highly Cited
2008
Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma
Synthetic oligodeoxynucleotides (ODNs), such as PF-3512676, that contain unmethylated cytosine-guanine motifs (CpG ODN) have been… 
Highly Cited
2007
Highly Cited
2007
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma
Purpose: PF-3512676 (formerly CpG 7909) is a novel Toll-like receptor 9–activating oligonucleotide with single-agent antitumor… 
Highly Cited
2007
Highly Cited
2007
Clinical setbacks for toll-like receptor 9 agonists in cancer
Cancer failures are not deterring interest in toll-like receptor agonists for other high profile indications. 
Highly Cited
2007
Highly Cited
2007
Intradermal CpG-B Activates Both Plasmacytoid and Myeloid Dendritic Cells in the Sentinel Lymph Node of Melanoma Patients
Purpose: A decrease in the frequency and activation state of dendritic cells in the sentinel lymph node (SLN) has been observed… 
Highly Cited
2006
Highly Cited
2006
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
PURPOSE The recent identification of toll-like receptors (TLRs) and respective ligands allows the evaluation of novel dendritic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)